CDE-001 is a chemically standardized phytoextract obtained from CARMA, a propietary variety of Cannabis sativa (CPVO 16305) with no psychotropic effect and considered as industrial hemp. CDE-001 contains CBG (cannabigerol) and CBD (cannabidiol) and other bioactive phenolic compounds. CDE-001 is being developed for topical treatment of skin inflammatory conditions including Atopic Dermatitis. CDE-001 is currently developed under a Joint Venture Agreement with Phytoplant Research SL, a Spanish company focused on developing products for phytotherapy.

Developed with DoPlanning